Every Form 4 that SOPHiA GENETICS SA (SOPH) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow SOPH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SOPH filings page.
SOPHiA GENETICS SA Chief Medical Officer Philippe Menu sold 5,000 ordinary shares on October 12, 2026, at a weighted average price of $7.2606 per share. The sales were made pursuant to a duly adopted trading plan under Rule 10b5-1(c); individual transaction prices ranged from $7.17 to $7.38. He directly held 195,993 shares after the sale.
SOPHiA GENETICS SA (SOPH) Chief Scientific Officer Zhenyu Xu sold 4,000 ordinary shares on October 13, 2026, at a weighted average price of $7.1818 per share. The shares were sold in multiple transactions at prices ranging from $7.09 to $7.24 under a Rule 10b5-1(c) trading plan. After the sale, Xu directly held 541,493 ordinary shares.
SOPHiA GENETICS SA Executive Chairman Jurgi Camblong sold 8,500 Ordinary Shares on October 12, 2026, at a weighted average price of $7.2554 per share. The shares were sold in multiple transactions at prices ranging from $7.15 to $7.38 per share, pursuant to a duly adopted Rule 10b5-1(c) trading plan. Camblong reported direct holdings of 3,387,150 shares following the sale.
SOPHiA GENETICS SA Chief Legal Officer Daan Van Well sold 6,168 ordinary shares on October 5, 2026, at a weighted average price of $8.1226 per share. The sales satisfied tax withholding obligations arising from restricted stock units vesting on October 2 and 3, 2026, and were made under a pre-established Rule 10b5-1(c) trading plan; the filing says they were not discretionary trades. Van Well directly held 332,716 shares after the sale.
SOPHiA GENETICS SA Chief People Officer Manuela Valente sold 4,240 ordinary shares on October 5, 2026, at a weighted average price of $8.1338 per share. The open-market sales satisfied tax withholding obligations arising from restricted stock unit vesting on October 2 and 3, 2026. They were made under a pre-established Rule 10b5-1(c) trading plan and were not discretionary. Manuela Valente directly held 206,210 ordinary shares after the sale.
SOPHiA GENETICS SA Chief Technology Officer Abhimanyu Verma sold 5,284 ordinary shares on October 5, 2026, at a weighted average price of $8.1243 per share. The sales satisfied tax withholding obligations arising from restricted stock unit vesting on October 2 and 3, 2026, and were made under a pre-established Rule 10b5-1(c) trading plan; the footnote says they were not discretionary trades. Verma directly held 166,887 shares after the sale.
SOPHiA GENETICS SA (SOPH) Chief Sales Officer Kevin Puylaert reported two direct sales of ordinary shares on October 5, 2026: 185 shares at $8.06 per share and 31 shares at $7.92 per share. No Rule 10b5-1 plan is reported.
George Cardoza, Chief Financial Officer of SOPHiA GENETICS SA, sold 1,592 ordinary shares on October 5, 2026, at a weighted-average price of $8.1014 per share. The sale satisfied tax withholding obligations arising from restricted stock units that vested on October 2, 2026. It was made under a pre-established Rule 10b5-1(c) trading plan adopted by Cardoza and was described as non-discretionary. His direct holdings following the sale were 306,726 ordinary shares.
SOPHiA GENETICS SA (SOPH) Chief Medical Officer Philippe Menu sold 7,394 ordinary shares on October 5, 2026, at a weighted average price of $8.1282 per share. The shares were sold in multiple transactions at prices from $7.91 to $8.30 to satisfy tax withholding obligations tied to restricted stock units that vested October 2 and 3, 2026. The sale was made under a pre-established Rule 10b5-1(c) trading plan adopted by Menu and did not represent discretionary trades; he directly held 200,993 shares afterward.
SOPHiA GENETICS SA (SOPH) Executive Chairman Jurgi Camblong sold 40,172 ordinary shares on October 5, 2026, at a weighted average price of $8.1282 per share; multiple transactions were priced from $7.90 to $8.35 per share, inclusive.
The sales were made in the open market to satisfy tax withholding obligations arising from restricted stock units that vested on October 2 and 3, 2026. They were effected under a pre-established Rule 10b5-1(c) trading plan and were not discretionary trades. Camblong directly held 3,395,650 ordinary shares after the sale.
Zhenyu Xu, Chief Scientific Officer of SOPHiA GENETICS SA, sold 7,394 ordinary shares on October 5, 2026, at a weighted average price of $8.1248 per share. The shares were sold in multiple open-market transactions to satisfy tax withholding obligations arising from restricted stock unit vesting on October 2 and 3, 2026. The sales were made under a pre-established Rule 10b5-1(c) plan and did not represent discretionary trades. Xu reported direct holdings of 545,493 shares after the sale; transaction prices ranged from $7.99 to $8.30 per share, inclusive.
SOPHiA GENETICS SA Chief Executive Officer and director Ross Muken sold 9,838 ordinary shares on October 5, 2026, at a weighted average price of $8.1288 per share, leaving him with 660,391 shares held directly. The shares were sold to satisfy tax withholding obligations arising from restricted stock units vesting on October 2 and 3, 2026, under a pre-established Rule 10b5-1(c) trading plan; the footnote says the sales were not discretionary. Sale prices ranged from $7.91 to $8.34 per share.
SOPHiA GENETICS SA (SOPH) reported that Chief Financial Officer George Cardoza sold 774 ordinary shares on September 21, 2026 at $8.33 per share, leaving him with 308,318 shares held directly. The footnote states these shares were sold in the open market solely to cover tax withholding obligations from restricted stock units that vested on September 18, 2026, under a pre-established Rule 10b5-1(c) trading plan, and that the trades were not discretionary.
SOPHiA GENETICS SA (SOPH) reported that Chief Executive Officer and director Ross Muken sold 422 Ordinary Shares on September 21, 2026 at $8.33 per share. According to the disclosure, the shares were sold in the open market solely to satisfy tax withholding obligations from restricted stock units that vested on September 18, 2026, under a pre-established Rule 10b5-1(c) trading plan, and are not discretionary trades. Following this transaction, Muken directly holds 670,229 Ordinary Shares.
SOPHiA GENETICS SA (SOPH) reported that Chief Medical Officer Philippe Menu sold 5,000 Ordinary Shares on September 14, 2026 in an open-market or private transaction at a weighted average price of $7.8833 per share, pursuant to a duly adopted Rule 10b5-1(c) trading plan, leaving him with 208,387 shares held directly.
SOPHiA GENETICS SA (SOPH) reports that Chief Scientific Officer Zhenyu Xu sold 4,000 Ordinary Shares on September 14, 2026 at a weighted average price of about $7.88 per share, in transactions executed under a duly adopted Rule 10b5-1(c) trading plan, leaving him with 552,887 shares held directly.
SOPHiA GENETICS SA (SOPH) reported that its Chief Legal Officer, Daan Van Well, sold 6,168 ordinary shares on September 11, 2026 in an open-market or private transaction. The weighted average sale price was about $7.63 per share, with individual trades between $7.55 and $7.85. After this sale, the officer directly held 338,884 ordinary shares. The transaction was made pursuant to a duly adopted Rule 10b5-1(c) trading plan.
SOPHiA GENETICS SA (SOPH) reported that Executive Chairman Jurgi Camblong sold 8,500 Ordinary Shares on September 10, 2026 in an open-market transaction at a weighted average price of about $7.66 per share, under a duly adopted Rule 10b5-1(c) trading plan. Following this sale, he directly holds 3,435,822 Ordinary Shares.
SOPHiA GENETICS SA (SOPH) director Kathy L. Hibbs reported selling 6,250 Ordinary Shares on September 8, 2026. The shares were sold at a weighted average price of $8.1308 per share in transactions ranging from $7.90 to $8.35, under a duly adopted Rule 10b5-1(c) trading plan. Following this sale, she directly holds 96,992 Ordinary Shares.
SOPHiA GENETICS SA (SOPH) reported that Chief Scientific Officer Zhenyu Xu sold 10,000 Ordinary Shares on August 27, 2026 in an open-market or private transaction under a Rule 10b5-1(c) trading plan. The weighted average sale price was $8.9096 per share, and Xu now holds 556,887 Ordinary Shares directly.
SOPHiA GENETICS SA (SOPH) reported that Chief Medical Officer Philippe Menu sold 5,000 Ordinary Shares on 2026-08-25. The shares were sold at a weighted average price of $8.6793 per share, in multiple trades between $8.37 and $8.84, pursuant to a Rule 10b5-1(c) trading plan. Following this transaction, Menu owned 213,387 Ordinary Shares directly.
SOPHiA GENETICS SA (SOPH) director Kathy L. Hibbs reported selling 6,250 Ordinary Shares on 2026-08-25 in an open market or private transaction at a weighted average price of $8.6773 per share, with individual trade prices ranging from $8.31 to $8.83. The sale was made pursuant to a duly adopted Rule 10b5-1(c) trading plan, and following this transaction she directly owns 103,242 Ordinary Shares.
SOPHiA GENETICS SA (SOPH) reported that Chief Technology Officer Abhimanyu Verma sold a total of 10,000 Ordinary Shares in two open-market transactions. On August 19, 2026, he sold 5,000 shares at $8.20 per share, and on August 24, 2026, he sold 5,000 shares at $8.80 per share. Both transactions were executed under a duly adopted Rule 10b5-1(c) trading plan, indicating they were pre-arranged.
SOPHiA GENETICS SA (SOPH) reported that Chief People Officer Manuela Valente exercised share options for 10,000 Ordinary Shares at an exercise price of $3.20 per share and, on the same date, sold 10,000 Ordinary Shares at a weighted average price of $7.9439 per share. The transactions were made pursuant to a duly adopted Rule 10b5-1(c) trading plan. The exercised options were fully vested, and following this exercise she continues to hold 554,276 derivative share options across remaining grant tranches with varying exercise prices, with the exercised option series expiring on January 1, 2029.
SOPHiA GENETICS SA (SOPH) reported that Chief Scientific Officer Zhenyu Xu sold a total of 20,000 Ordinary Shares in open-market or private transactions under a duly adopted Rule 10b5-1(c) trading plan. The sales occurred on August 19–21, 2026, at weighted average prices of $7.94, $8.41, and $8.40, each representing multiple trades within narrow price ranges.
Philippe Menu, Chief Medical Officer of SOPHiA GENETICS SA, sold 5,000 Ordinary Shares of the company on 2026-08-12 in an open-market transaction under a duly adopted Rule 10b5-1(c) trading plan. The weighted average sale price was $7.5159 per share, with individual trades executed between $7.40 and $7.60 per share. Following this sale, Menu directly holds 218,387 Ordinary Shares.
SOPHiA GENETICS SA Chief Scientific Officer Zhenyu Xu reported a sale of 4,000 Ordinary Shares on August 13, 2026. The shares were sold at a weighted average price of $7.5191 per share, in multiple trades between $7.43 and $7.62. After this transaction, Xu directly holds 586,887 Ordinary Shares. The sale was made pursuant to a duly adopted Rule 10b5-1(c) trading plan.
SOPHiA GENETICS SA Chief Technology Officer Abhimanyu Verma reported a sale of 5,000 Ordinary Shares of SOPH on 2026-08-07 at $7.60 per share in an open market or private transaction. After this transaction, he directly holds 182,171 Ordinary Shares. The sale was made pursuant to a duly adopted Rule 10b5-1(c) trading plan.
SOPHiA GENETICS SA Executive Chairman Jurgi Camblong reported two non-derivative stock sales of Ordinary Shares pursuant to a duly adopted Rule 10b5-1(c) trading plan. On August 7, 2026, he sold 20,000 shares at a weighted average price of $7.227, in multiple trades between $7.20 and $7.27. On August 10, 2026, he sold 8,500 shares at a weighted average price of $7.6081, in multiple trades between $7.50 and $7.80. Post-transaction share holdings are not specified in this filing.
SOPHiA GENETICS SA Chief Scientific Officer Xu Zhenyu reported option exercises and share sales in early August 2026. He exercised options for 10,000 Ordinary Shares at $3.2800 per share and sold 20,000 Ordinary Shares at prices between $7.00 and $7.56 under a Rule 10b5-1(c) trading plan, while retaining 975,041 derivative share options.
SOPHiA GENETICS SA reported that Chief Technology Officer Abhimanyu Verma sold 5,000 Ordinary Shares on 2026-08-04 at a weighted average price of $6.9543 per share, in multiple trades between $6.95 and $6.98. The sale was made pursuant to a duly adopted Rule 10b5-1(c) trading plan, and Verma now holds 187,171 Ordinary Shares directly.
SOPHiA GENETICS SA Executive Chairman Jurgi Camblong reported selling 20,000 Ordinary Shares on 2026-08-04 in an open-market transaction under a duly adopted Rule 10b5-1(c) trading plan. The shares were sold at a weighted average price of $6.9206, within a $6.90–$6.98 range, leaving him with 3,472,822 shares held directly.
SOPHiA GENETICS SA reports that Chief Scientific Officer Zhenyu Xu sold 10,000 Ordinary Shares on August 4, 2026 at a weighted average price of $6.9168 per share under a duly adopted Rule 10b5-1(c) trading plan, in trades priced between $6.90 and $6.95, leaving 600,887 shares held directly.
SOPHiA GENETICS SA reported that Chief Medical Officer Philippe Menu executed a sale of 5,000 Ordinary Shares on 2026-07-27. The shares were sold at a weighted average price of $5.6611 per share, with individual trades occurring between $5.57 and $5.83. The sale was carried out under a duly adopted Rule 10b5-1(c) trading plan, indicating it was pre-arranged. After this transaction, Menu directly holds 223,387 Ordinary Shares of SOPHiA GENETICS SA.
SOPHiA GENETICS SA Executive Chairman and director Jurgi Camblong reported option exercises and share sales executed pursuant to a duly adopted Rule 10b5-1(c) trading plan. On July 20, 2026, he exercised options for 4,581 ordinary shares at $3.16 per share and sold 4,581 shares at a weighted average $6.1654, in multiple trades between $6.10 and $6.20, plus 19,800 shares at a weighted average $6.3233, in trades between $6.30 and $6.37. On July 21, 2026, he sold 20,000 ordinary shares at a weighted average $6.6327, in trades between $6.60 and $6.72. A footnote states he continues to hold 4,641,476 derivative share options across remaining grant tranches.
SOPHiA GENETICS SA Chief Medical Officer Philippe Menu completed an open-market sale of 5,000 Ordinary Shares on 2026-07-13 at a weighted average price of $5.701 per share, with individual trade prices between $5.55 and $5.79, pursuant to a duly adopted Rule 10b5-1(c) trading plan. Following the transaction, he directly holds 228,387 Ordinary Shares.
SOPHiA GENETICS SA Chief Scientific Officer Zhenyu Xu completed an open-market sale of 4,000 Ordinary Shares on July 13, 2026, at a weighted average price of $5.7048 per share. The transaction was made under a duly adopted Rule 10b5-1(c) trading plan, and Xu now directly holds 610,887 Ordinary Shares.
SOPHiA GENETICS SA Executive Chairman Jurgi Camblong reported an open-market sale of 8,500 Ordinary Shares on July 10, 2026 at a weighted average price of $5.6225 per share. The transaction was made pursuant to a Rule 10b5-1(c) trading plan, and he continues to hold 3,532,622 shares directly. The shares were sold in multiple trades at prices between $5.53 and $5.77.
SOPHiA GENETICS SA Executive Chairman Jurgi Camblong reported an open-market sale of 17,685 Ordinary Shares at an average price of $5.2772 per share. According to the filing, the shares were sold to satisfy tax withholding obligations tied to restricted stock units that vested on July 3, 2026, under a pre-established Rule 10b5-1(c) trading plan. After this transaction, Camblong directly holds 3,541,122 Ordinary Shares, indicating the sale is small relative to his remaining stake and was executed on a non-discretionary basis.
SOPHiA GENETICS SA Chief Financial Officer George Cardoza sold 1,592 Ordinary Shares in an open‑market transaction. The weighted average sale price was $5.2886 per share. According to the disclosure, the sale was made to cover tax withholding obligations from restricted stock units that vested on July 2, 2026 and was executed under a pre‑established Rule 10b5‑1(c) trading plan. After this tax‑related sale, Cardoza directly holds 309,092 Ordinary Shares.
SOPHiA GENETICS SA Chief People Officer Manuela Valente sold 4,241 Ordinary Shares in an open-market transaction. The shares were sold at a weighted average price of $5.053 per share to cover tax withholding obligations tied to restricted stock units vesting on July 2 and July 3, 2026, under a pre-established Rule 10b5-1(c) trading plan. After this sale, she directly holds 210,450 Ordinary Shares.
SOPHiA GENETICS SA Chief Technology Officer Abhimanyu Verma reported a sale of 5,285 Ordinary Shares in an open-market transaction. The weighted average sale price was about $5.10 per share, with individual trades between $4.97 and $5.41.
According to the footnotes, these shares were sold to satisfy tax withholding obligations tied to restricted stock units that vested on July 2 and July 3, 2026. The transactions were executed under a pre-established Rule 10b5-1(c) trading plan and are described as non-discretionary. After the sale, Verma directly holds 192,171 Ordinary Shares.
SOPHiA GENETICS SA Chief Scientific Officer Zhenyu Xu sold 7,393 Ordinary Shares in an open-market transaction at a weighted average price of $5.1727 per share. The sale was executed to cover tax withholding obligations from recent restricted stock unit vesting under a pre-established Rule 10b5-1(c) trading plan and does not represent a discretionary trade. Following this transaction, Xu directly holds 614,887 Ordinary Shares, indicating he retains a large continuing stake in the company.
SOPHiA GENETICS SA Chief Executive Officer Ross Muken reported an open-market sale of 9,838 Ordinary Shares at a weighted average price of $5.22 per share. According to the footnotes, the sale was made solely to satisfy tax withholding obligations tied to restricted stock units that vested on July 2 and July 3, 2026, under a pre-established Rule 10b5-1(c) trading plan and was not a discretionary trade. Following these transactions, he directly holds 670,651 Ordinary Shares. The shares were sold in multiple trades at prices between $4.97 and $5.43.
SOPHiA GENETICS SA Chief Sales Officer Kevin Puylaert reported small insider sales tied to tax obligations. On July 6, 2026, he sold a total of 216 Ordinary Shares in open-market transactions at prices between $5.0251 and $5.0862 per share.
According to the footnotes, these were non-discretionary “sell to cover” trades executed to satisfy taxes from restricted stock units that vested on July 2 and July 3, 2026. After these transactions, he continues to hold 147,948 Ordinary Shares directly.
SOPHiA GENETICS SA Chief Medical Officer Philippe Menu sold 7,393 ordinary shares of the company on July 6, 2026 at a weighted average price of $5.1611 per share. According to the disclosure, these open-market sales were made to satisfy tax withholding obligations from restricted stock units that vested on July 2 and July 3, 2026, and were executed under a pre-established Rule 10b5-1(c) trading plan, meaning they were not discretionary trades. After the sale, Menu directly holds 233,387 ordinary shares, indicating he maintains a substantial ongoing equity position in the company.
SOPHiA GENETICS SA Executive Chairman Jurgi Camblong reported an open-market sale of 22,486 Ordinary Shares at a weighted average price of $5.255 per share. According to the filing, the sale was made to satisfy tax withholding obligations from restricted stock unit vesting and was executed under a pre-established Rule 10b5-1(c) trading plan, described as non-discretionary. After this transaction, he directly holds 3,558,807 Ordinary Shares.
SOPHiA GENETICS SA Executive Chairman Jurgi Camblong reported both option exercises and share sales in late June. On June 29–30, he sold a total of 83,679 Ordinary Shares in multiple open‑market transactions at prices including $6.30, $6.0215, $6.00 and $5.8670 per share, under a pre‑arranged Rule 10b5‑1(c) trading plan.
He also exercised share options to acquire 63,479 Ordinary Shares at an exercise price of $3.16 per share, converting previously granted options into stock. After these transactions, he directly holds 3,581,293 Ordinary Shares and continues to hold 4,646,057 derivative stock options across remaining grant tranches, indicating a substantial ongoing exposure to the company’s equity despite the sales.
SOPHiA GENETICS SA Chief Executive Officer Jurgi Camblong reported an exercise-and-sell transaction involving the company’s ordinary shares. He exercised 31,940 share options at an exercise price of $3.16 per share and sold a total of 51,442 ordinary shares in open-market trades at weighted average prices around $5.73–$5.84, in multiple transactions within disclosed ranges. These sales were made pursuant to a duly adopted trading plan under Rule 10b5-1(c). Following the transactions, he directly owns 3,601,493 ordinary shares and holds 4,709,536 derivative stock options across remaining grant tranches with varying exercise prices.
SOPHiA GENETICS SA Chief Technology Officer Abhimanyu Verma sold 6,944 Ordinary Shares in an open-market transaction at a weighted average price of about $5.51 per share. According to the disclosure, the sale was made to cover tax withholding obligations from restricted stock unit vesting under a pre-established Rule 10b5-1(c) trading plan and was not a discretionary trade. Following this tax-related sale, he continues to hold 197,456 Ordinary Shares directly.